Investor Relations

Press Releases

Date Title and Summary View
Feb 11, 2019
Company now focused on completing plan to resubmit NDA in first half of 2019 . PRINCETON, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced topline results from a comparative wear study testing the adhesion of Twirla ®
Feb 07, 2019
PRINCETON, N.J. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the 2019 BIO CEO & Investor conference on Tuesday February 12, 2019 at 10:30 AM
Jan 10, 2019
Discussions with FDA on Design of Comparative Wear Study of Twirla ® and Xulane ® Completed  Cash Expected to Enable Company to Fund Operations into Second Quarter of 2019 PRINCETON, N.J. , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company,
Dec 18, 2018
PRINCETON, N.J. , Dec. 18, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the Biotech Showcase 2019 on Tuesday January 8, 2019 at 10:00 AM Pacific Time .
Dec 13, 2018
Expects to Announce Results of Meeting After Receipt of Final Minutes from FDA PRINCETON, N.J. , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced that on December 11, 2018 , it met with the U.S.
Nov 01, 2018
Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and nine months ended September 30, 2018 and provided
Oct 24, 2018
PRINCETON, N.J. , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced an oral presentation regarding predictors of pregnancy in the Phase 3 SECURE study of the investigational low-dose, once-weekly contraceptive patch, AG200-15
Oct 09, 2018
PRINCETON, N.J. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has received a response from FDA’s Office of New Drugs (“OND”) concerning the Company’s formal dispute resolution request.  The Company had appealed the
Aug 03, 2018

Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and six months ended June 30, 2018 and provided a

Jul 24, 2018

Company Plans to Appeal to the FDA’s Office of New Drugs PRINCETON, N.J. , July 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX) (the “Company”), a women’s healthcare company, today announced that the Office Director of the FDA’s Office of Drug Evaluation III (ODEIII) has